ArticleFood science & nutrition2026
Preventive Effect of Gallic Acid-Loaded Carrageenan Nanoparticles Against Cerebral Ischemia/Reperfusion Injury in Rat: Modulation of Oxidative Pathway.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymeric nanocarriers represent a promising drug delivery platform for neurological disorders. This study evaluated the neuroprotective effects of gallic acid-loaded carrageenan nanoparticles (GA-CG NPs) in a rat model of global cerebral ischemia/reperfusion (I/R) injury. Rats were randomly assigned to four groups, including Control, I/R, GA (free gallic acid), and GA-CG NPs. GA and GA-CG NPs were administered orally for 14 days before I/R induction. Following I/R, depressive-like behaviors and cognitive function, cerebral infarct volume, activities of antioxidant enzymes (SOD, CAT, GPx), glutathione (GSH), dopamine (DA) levels, and lipid peroxidation (MDA) were evaluated. GA-CG NPs pretreatment significantly improved behavioral disorders and reduced infarct volume compared to the I/R group. The nanoparticle formulation enhanced antioxidant defenses, increasing SOD, CAT, GPx, GSH, and DA levels while decreasing MDA. Notably, GA-CG NPs demonstrated superior neuroprotection to free GA across all measured parameters. These findings indicate that GA-CG NPs effectively prevent I/R-induced oxidative brain damage and may represent a promising therapeutic strategy for cerebral ischemia complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.